Lawton Colleen A, DeSilvio Michelle, Lee W Robert, Gomella Leonard, Grignon David, Gillin Michael, Morton Gerard, Pisansky Thomas, Sandler Howard
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):39-47. doi: 10.1016/j.ijrobp.2006.08.016. Epub 2006 Nov 2.
To evaluate the effectiveness of transrectal ultrasound-guided permanent radioactive (125)I implantation of the prostate for organ-confined adenocarcinoma of the prostate compared with historical data of prostatectomy and external beam radiotherapy within a cooperative group setting.
Patients accrued to this study had histologically confirmed, locally confined, adenocarcinoma of the prostate with clinical Stage T1b, T1c, or T2a, no nodal or metastatic disease, prostate-specific antigen level of < or =10 ng/mL, and Gleason score of < or =6. All patients underwent transrectal ultrasound-guided radioactive (125)I permanent seed implantation into the prostate. The prescribed dose was 145 Gy to the prostate planning target volume.
A total of 27 institutions accrued a total of 101 patients to this protocol, with no institution accruing >8 patients. Six patients were ineligible, leaving 95 properly entered as eligible in the study. The median follow-up was 5.3 years (range, 0.4-6.5 years). At 5 years, 5 patients had local failure, 1 had evidence of distant failure, and 6 (6%) had biochemical failure. The overall survival rate at 5 years was 96.7%. At last follow-up, no patient had died of prostate cancer or related toxicities. Eight patients had a maximal acute toxicity level of 3, and no patient had Grade 4 or 5 acute toxicity. During follow-up, 2 patients had maximal Grade 3 toxicity, both related to bladder issues, and no patient experienced Grade 4 or 5 toxicity.
The results of this clinical protocol (a multi-institutional trial of brachytherapy for localized adenocarcinoma of the prostate) have demonstrated that this type of trial can be successfully completed through the Radiation Therapy Oncology Group. Biochemical disease-free survival was comparable with other brachytherapy published series and with the results after surgery and external beam radiotherapy.
在协作组环境下,将经直肠超声引导下前列腺永久性放射性(125)I植入治疗前列腺局限性腺癌的有效性与前列腺切除术和外照射放疗的历史数据进行比较。
纳入本研究的患者经组织学证实为前列腺局限性腺癌,临床分期为T1b、T1c或T2a,无淋巴结或远处转移,前列腺特异性抗原水平≤10 ng/mL,Gleason评分≤6。所有患者均接受经直肠超声引导下前列腺永久性放射性(125)I粒子植入。前列腺计划靶体积的处方剂量为145 Gy。
共有27个机构为本方案纳入了101例患者,没有一个机构纳入超过8例患者。6例患者不符合条件,95例符合条件并正确纳入研究。中位随访时间为5.3年(范围0.4 - 6.5年)。5年时,5例患者出现局部复发,1例有远处转移证据,6例(6%)出现生化复发。5年总生存率为96.7%。在最后一次随访时,没有患者死于前列腺癌或相关毒性反应。8例患者的最大急性毒性等级为3级,没有患者出现4级或5级急性毒性反应。随访期间,2例患者出现最大3级毒性反应,均与膀胱问题有关,没有患者出现4级或5级毒性反应。
本临床方案(一项针对局限性前列腺腺癌近距离放疗的多机构试验)的结果表明,这类试验可以通过放射治疗肿瘤学组成功完成。生化无病生存率与其他已发表的近距离放疗系列以及手术和外照射放疗后的结果相当。